Which account would you like to be logged in as?

Forgot Password?

Sign Up!

Visa/MasterCard and Discover Users
Flip your credit card over and look at the signature box. You should see either the entire 16-digit credit card number or just the last four digits followed by a special 3-digit code. The 3-digit code is your Card Security Code.

American Express Credit Card Users
Look for the 4-digit code printed on the front of your card just above and to the right of your main credit card number. The 4-digit code is your card Identification Number (CID).

What is a discount code?
Generic discount code text needs to go here

jul 12
Release date

Advances in the Management of NSCLC: Highlights from the 2011 ASCO Annual Meeting

Lung Cancer

MEDIA: Newsletter

Estimated time to complete activity: 1.0 hour | Release date: Tuesday, July 12, 2011 | Expiration date: Wednesday, July 11, 2012


The 2011 American Society of Clinical Oncology (ASCO) Annual Meeting held June 3-7, 2011, in Chicago, Illinois, provided a comprehensive review of key experimental and clinical data presented at the conference. Included in this newsletter are highlights from the conference covering major plenary sessions, key symposia, and targeted oral and poster presentations on the advances in the management of non-small cell lung cancer (NSCLC).


Treatment of Advanced-Stage NSCLC
Treatment of Early-Stage NSCLC


Gregory A. Otterson, MD, FACP

Professor of Internal Medicine
Associate Director for Education
Co-Director, Thoracic Oncology
Division of Medical Oncology
Associate Director
Hematology and Medical Oncology Fellowship Program
Ohio State University Medical Center
Columbus, Ohio

Heather Wakelee, MD

Associate Professor
Department of Medicine, Division of Oncology
Co-Director, Thoracic Oncology Clinical Research Group
Stanford University
Stanford, California


The intended audience for this activity is medical, surgical, and radiation oncologists, and oncology specialty pharmacists, charged with the care of patients with lung cancer.


At the conclusion of this activity, participants should be able to:

  • Describe the most current advances for the diagnosis and staging of patients with lung cancer
  • Describe the rationale for the development and integration of new therapeutic approaches in lung cancer
  • Discuss the clinical implications of the results from pivotal clinical trials that have impacted the use of new approaches and strategies for the treatment of NSCLC
  • Review ongoing clinical trial designs of novel surgical, radiotherapeutic, and chemotherapeutic treatment strategies for the management of NSCLC


Accreditation Statement
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Educational Concepts Group, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ACPE Logo Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

Educational Concepts Group, LLC designates this continuing education activity for 1.0 contact hour (0.10 CEU) (UAN 0199-0000-11-019-H01-P).

Type of activity: Knowledge-based


There are no fees for participating and receiving CME/CE credit for this activity. During the period Tuesday, July 12, 2011 through Wednesday, July 11, 2012, participants must 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.


Physicians and pharmacists who complete the post-activity assessment with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.


It is the policy of ECG that the faculty, authors, planners, and other persons who may influence content of this CME/CE activity disclose all relevant financial relationships with commercial interests in order to allow ECG to identify and resolve any potential conflicts of interest.

The Following Faculty Members Have Declared Relevant Financial Relationships

Gregory A. Otterson, MD, FACP Grants/Research Support Celgene Corporation
Pfizer Inc
Tragara Pharmaceuticals, Inc.
Consultant Fees Celgene Corporation
Heather Wakelee, MD Grants/Research Support AstraZeneca
Bayer HealthCare Pharmaceuticals, Inc.
Exelixis, Inc.
Lilly USA, LLC
Pfizer Inc
Regeneron Pharmaceuticals, Inc.

Staff Disclosure
Planners and managers at ECG have no relevant financial relationships to disclose.


The editors wish to thank Lea Ann Hansen, PharmD, BCOP, for assistance in writing this document.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.


This activity is supported by educational grants from the following: Agennix AG, Celgene Corporation, Genentech BioOncology, Teva Pharmaceuticals, OSI Pharmaceuticals, Inc.


For further information, please contact:
Educational Concepts Group, LLC
1300 Parkwood Circle SE, Suite 325
Atlanta, Georgia 30339
Phone: 1.866.933.1681
Fax: 1.866.933.1692

None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.

Yes, I have read the information above and am interested in participating.